BMRN
NASDAQ · Biotechnology
Biomarin Pharmaceutical Inc
$63.94
-1.14 (-1.75%)
Performance
1D
—
1W
—
1M
—
3M
+13.17%
6M
+15.02%
1Y
+18.54%
YTD
+7.55%
Open$65.25
Previous Close$65.08
Day High$65.29
Day Low$63.84
52W High$70.98
52W Low$49.26
Volume—
Avg Volume1.78M
Market Cap12.60B
P/E Ratio172.64
EPS$0.36
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$58.45
Above
SMA 200
$56.57
Above
RSI (14)
78.3
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
35 analysts
Price Target
+97.7% upside
Current
$63.94
$63.94
Target
$126.44
$126.44
$89.21
$126.44 avg
$194.19
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.22B | 2.79B | 1.41B |
| Net Income | 348.24M | 271.59M | -2,303,166 |
| Profit Margin | 10.8% | 10.3% | -0.2% |
| EBITDA | 428.06M | 352.39M | -4,073,088 |
| Free Cash Flow | — | — | -1,983,877 |
| Rev Growth | +15.4% | +15.4% | -7.9% |
| Debt/Equity | 0.10 | 0.10 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.96 | -0.02% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $385.65 | +1.55% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.11 | -0.52% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $508.34 | -1.55% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $784.85 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $239.56 | -2.42% | 40.0 | 32.33B |